Skip to content

Choline Nutritional Status Of Children With Cystic Fibrosis X-Sectional Study

Choline Nutritional Status Of Children With Cystic Fibrosis X-Sectional Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01150136
Enrollment
57
Registered
2010-06-24
Start date
2007-10-31
Completion date
2009-03-31
Last updated
2015-04-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cystic Fibrosis

Keywords

choline, cystic fibrosis, methyl metabolism, oxidative stress

Brief summary

Cystic fibrosis (CF) is the most common lethal, inherited disorder among Caucasians. Choline is an essential vitamin and as a methyl donor is critically needed to support the normal metabolism. Our previous studies have demonstrated that children with CF have depleted levels of choline. The purpose of this study is to gather data on the status of choline and related metabolites in children with Cystic Fibrosis by age and gender. The hypothesis for this study is that in children with CF, deficiency of choline and related metabolites will increase with increasing age.

Detailed description

The objective of this clinical project is to determine the status of choline and related metabolites in a large group of children with Cystic Fibrosis (CF). Based on the results it will be possible to determine which children are deficient or at risk for choline deficiency, and might benefit most from supplementation to sustain improvement in the plasma choline, and its metabolites. This will be a cross-sectional study that will, over a 6 month period, look to enroll as many patients as possible from 140 children with CF who are seen regularly at the CF Clinic at B.C.'s Children's Hospital. The study will involve the collection of blood and urine at the time of a scheduled appointment. All procedures for enrollment, collection of chart data and blood samples will follow procedures used in our previous studies. Body weight and height will be measured and routine blood work including liver enzymes, hematology, serum zinc, selenium and vitamins A and E will be completed as part of the clinic appointment. CF genotype, gender, birth date, hematology, clinical chemistry, anthropometric and nutritional measures, liver ultrasound, biopsy reports where available, pancreatic function (elastase, chymotrypsin/secretin-CCK) and all medications including mineral, vitamin and nutritional and enzyme supplements will be recorded from chart data. Blood samples will be used for analyses of choline and its metabolites and various biomarkers in redox pathways. A urine sample will be collected and used to assay excretion of related metabolites. Creatine will be analyzed to avoid the need for quantitative 24 hour urine collection.

Interventions

None listed

Sponsors

Cystic Fibrosis Foundation
CollaboratorOTHER
University of British Columbia
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
No minimum to 17 Years
Healthy volunteers
Yes

Inclusion criteria

* children with proven CF and known genotype. * age 0-17 yr. * outpatients of the CF Clinic at the British Columbia (B.C.) Children's Hospital. * Children without CF or any other known disease.

Exclusion criteria

* children with CF receiving parenteral nutrition during the previous week. * children who are hospitalized. * children with any health problems other than CF that might in the opinion of the investigators influence dietary choices, growth, choline or methyl metabolites.

Design outcomes

Primary

MeasureTime frame
The change in plasma choline and its metabolites with increasing age in children with CF compared to a healthy reference group without CF12 months

Secondary

MeasureTime frame
The relationship between choline and acetylcholine, and markers of oxidative stress, inflammation and disturbed methyl metabolism12 months

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 29, 2026